CG Oncology (CGON) Non-Current Deferred Tax Liability (2025)

CG Oncology (CGON) posted Non-Current Deferred Tax Liability of $30000.0 for Q4 2025.

CG Oncology (CGON) Non-Current Deferred Tax Liability (2025) Analysis & Trends

CG Oncology's Non-Current Deferred Tax Liability history runs 1 years deep, the most recent figure standing at $30000.0 for Q4 2025.

Quarterly Non-Current Deferred Tax Liability changed N/A year-over-year to $30000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $30000.0 (changed N/A YoY) and the FY2025 annual result came in at $30000.0, changed N/A from the prior year.
Non-Current Deferred Tax Liability was $30000.0 for Q4 2025 at CG Oncology.
Across five years, Non-Current Deferred Tax Liability topped out at $30000.0 in Q4 2025 and bottomed at $30000.0 in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	67,072.09 Bn	67,072.09 Bn	-
2	Nanobiotix	1,894.61 Bn	1,894.55 Bn	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-
4	BeOne Medicines	471.64 Bn	466.85 Bn	1.35 Bn
5	Vertex Pharmaceuticals	121.72 Bn	114.47 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	68.28 Bn	59.52 Bn	3.31 Bn
7	Belite Bio	61.40 Bn	61.40 Bn	-
8	Argenx Se	56.94 Bn	56.94 Bn	1.18 Bn
9	Revolution Medicines	37.37 Bn	37.37 Bn	-
10	CG Oncology	5.86 Bn	5.86 Bn	-1.88 Mn

Download Data

Date	Value
Dec 31, 2025	30,000.00
Dec 31, 2025	30,000.00